- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07:42 | UBS initiates Olema Pharmaceuticals stock with Buy rating, $45 target | ||
| 07:42 | Oruka Therapeutics stock initiated with Buy rating at UBS on cancer drug potential | ||
| 07:42 | UBS assumes coverage on Immunocore stock with Buy rating, $55 target | ||
| 07:42 | UBS initiates Nuvation Bio stock with Neutral rating, $10 price target | ||
| 07:42 | UBS initiates coverage on MBX Biosciences stock with Buy rating | ||
| 07:42 | UBS initiates Kodiak Sciences stock with Buy rating, $50 price target | ||
| 07:42 | UBS assumes coverage on Inventiva stock with Buy rating, $12 target | ||
| 07:42 | Denali Therapeutics stock rating initiated at Buy by UBS on Hunter syndrome drug potential | ||
| 07:42 | AnaptysBio stock rating initiated at Buy by UBS with $70 price target | ||
| 07:42 | Ideaya Biosciences stock gets Buy rating from UBS with $50 price target | ||
| 07:30 | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| 07:30 | Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline | ||
| 07:30 | Stifel downgrades Portillo's stock rating to Hold on growth concerns | ||
| 07:30 | Devyani International stock maintains Overweight rating at JPMorgan | ||
| 07:30 | UBS assumes coverage of Pfizer stock with Neutral rating, $25 target | ||
| 07:30 | BMO Capital downgrades Union Pacific stock on merger uncertainty | ||
| 05:42 | Praxis Precision Medicines prices public offering at $260 per share | ||
| 03:54 | Crinetics Pharmaceuticals prices public offering at $45.95 per share | ||
| 02:42 | Sunrise Wind challenges US offshore lease suspension order | ||
| 02:30 | Amrize to acquire West Texas aggregates leader PB Materials | ||
| 02:30 | Galantas to acquire Chile's Andacollo Oro gold project for $32 million | ||
| 02:18 | Alcon terminates merger agreement with STAAR Surgical | ||
| 02:18 | cathie wood's ARK stock trades highlight major moves in Roblox and Meta | ||
| 01:06 | AAR Q2 FY26 presentation: 16% sales growth and strategic acquisitions boost outlook | ||
| 00:30 | Arrowhead Pharmaceuticals plans to offer $700 million in securities |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .